9 completed, 5 unknown, 2 recruiting, 1 active not recruiting. 19 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 19 | Completed 9, Unknown 5, Recruiting 2, Active not recruiting 1, Terminated 1, Withdrawn 1 |
Follow IgA Nephropathy: new trials by email Literature Review of IgA Nephropathy trials Research Report on IgA Nephropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nefecon and Ambrisentan in IgA Nephropathy "Nefecon®","Ambrisentan" - IgA Nephropathy, Chronic Kidney Disease | Phase 4 | Recruiting | The First Hospital of Jilin University | 129 | 2025-09-01 | 2025-09-15 |
| Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy? Oral prednisolone and SoC, Gut-directed budesonide and SoC, Mycophenolate mofetil (MMF) and SoC - IgA Nephropathy, Renal Insufficiency, Chronic | Phase 4 | Recruiting | Christian Medical College, Vellore, India | 585 | 2025-02-15 | 2025-07-14 |
| Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy TARPEYO® - IgA Nephropathy | Phase 4 | Active not recruiting | Calliditas Therapeutics AB | 60 | 2024-12-17 | 2026-09-24 |
| Rituximab and RASi in Patients with IgAN Rituximab, RAS 2410 - IgA Nephropathy | Phase 4 | Completed | Nan Chen,MD | 116 | 2020-07-01 | 2025-03-14 |
| A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy rituximab group - IgA Nephropathy | Phase 4 | Unknown | XIEJINGYUAN | 116 | 2020-06-20 | 2023-04-21 |
| Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy prednisone and cyclophosphamide, prednisone alone - IgA Nephropathy | Phase 4 | Unknown | Guangdong Provincial People's Hospital | 133 | 2016-12-01 | 2017-07-17 |
| Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy Mycophenolate Mofetil, ACE inhibitor, Corticosteroid - IgA Nephropathy | Phase 4 | Unknown | Yonsei University | 100 | 2016-06-01 | 2016-12-05 |
| Acthar on Proteinuria in IgA Nephropathy Patients Acthar 80 unit injection - IgA Nephropathy, Proteinuria | Phase 4 | Withdrawn | Baylor College of Medicine | 2015-02-01 | 2017-04-05 | |
| Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy Losartan, Abelmoschus manihot - IgA Nephropathy | Phase 4 | Unknown | Chen Xiangmei | 1600 | 2014-09-01 | 2016-07-06 |
| Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy prednisone plus cyclophosphamide, Prednisone alone - IgA Nephropathy | Phase 4 | Unknown | Guangdong Provincial People's Hospital | 135 | 2012-12-01 | 2017-07-14 |
| Pilot Study of Velcade® in IgA Nephropathy Bortezomib (Velcade®) - Chronic Kidney Disease, IgA Nephropathy | Phase 4 | Completed | The Rogosin Institute | 11 | 2010-07-01 | 2018-11-16 |
| Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Aliskiren, Valsartan - Proteinuric Kidney Disease, Diabetic Nephropathy | Phase 4 | Terminated | Columbia University | 46 | 2009-09-01 | 2014-05-15 |
| Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade Aliskiren - IgA Nephropathy | Phase 4 | Completed | The University of Hong Kong | 25 | 2009-07-01 | 2015-07-03 |
| Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy Intravenous Rituximab, ACE/ARB, Omega-3 Fatty Acid Fish Oil Supplement - IgA Nephropathy | Phase 4 | Completed | Mayo Clinic | 34 | 2009-02-01 | 2017-02-01 |
| A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy Valsartan, Probucol, Placebo - Glomerulonephritis, IGA Nephropathy | Phase 4 | Completed | Guangdong Provincial People's Hospital | 75 | 2007-05-01 | 2013-08-28 |
| Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy Calcitriol - IGA Nephropathy | Phase 4 | Completed | Chinese University of Hong Kong | 10 | 2006-05-01 | 2009-01-30 |
| Mycophenolate Mofetil for IgA Nephropathy mycophenolate mofetil, angiotensin blockade - IGA Nephropathy | Phase 4 | Completed | The University of Hong Kong | 40 | 2002-03-01 | 2009-03-17 |
| "Steroids and Azathioprine Versus Steroids Alone in IgAN" steroids plus azathioprine, steroids - IGA Nephropathy | Phase 4 | Completed | A. Manzoni Hospital | 206 | 1998-05-01 | 2008-09-19 |
| Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy ENALAPRIL VALSARTAN METHYLPREDNISONE - IGA Nephropathy | Phase 4 | Completed | Hospital Britanico | 20 | 1996-01-01 | 2006-11-01 |
Glomerulonephritis, IGA (19) · Proteinuria (11) · Renal Insufficiency, Chronic (4) · Glomerulonephritis (3) · Kidney Failure, Chronic (2) · Diabetic Nephropathies (1) · Glomerulonephritis, Membranous (1) · Glomerulosclerosis, Focal Segmental (1) · IgA Vasculitis (1)
Autoimmune Diseases (19) · Female Urogenital Diseases (19) · Female Urogenital Diseases and Pregnancy Complications (19) · Immune System Diseases (19) · Kidney Diseases (19) · Male Urogenital Diseases (19) · Nephritis (19) · Urogenital Diseases (19) · Urologic Diseases (19) · Glomerulonephritis (16) · Pathological Conditions, Signs and Symptoms (13) · Signs and Symptoms (12) · Urination Disorders (11) · Urological Manifestations (11) · Chronic Disease (6)
Mycophenolic Acid (3) · Angiotensin-Converting Enzyme Inhibitors (2) · Cyclophosphamide (2) · Prednisolone (2) · Prednisone (2) · Rituximab (2) · Valsartan (2) · aliskiren (2) · Adenosine Triphosphate (1) · Adrenal Cortex Hormones (1) · Angiotensin Receptor Antagonists (1) · Azathioprine (1) · Bortezomib (1) · Budesonide (1) · Calcitriol (1)
Guangdong Provincial People's Hospital (3) · The University of Hong Kong (2) · A. Manzoni Hospital (1) · Baylor College of Medicine (1) · Calliditas Therapeutics AB (1) · Chen Xiangmei (1) · Chinese University of Hong Kong (1) · Christian Medical College, Vellore, India (1) · Columbia University (1) · Hospital Britanico (1) · Mayo Clinic (1) · Nan Chen,MD (1) · The First Hospital of Jilin University (1) · The Rogosin Institute (1) · XIEJINGYUAN (1)
China (9) · United States (5) · Argentina (1) · Hong Kong (1) · India (1) · Italy (1) · Puerto Rico (1) · South Korea (1) · Switzerland (1)
Antonello Pani, MD (1) · Cheuk-Chun Szeto, MD (1) · Choli Hartono, MD (1) · Claudio Ponticelli, MD (1) · Claudio Pozzi, MD (1) · David Sheikh-Hamad, MD (1) · Fernando C. Fervenza, M.D. (1) · Francesco Locatelli, MD (1) · George T John, DM, FRCP, FRACP (1) · Gian B Fogazzi, MD (1) · Jingyuan Xie (1) · Jonathan Barratt, PhD, FRCP (1) · Krassimir Mitchev (1) · Paolo Altieri, MD (1)
PMID 38299639, PMID 26032537, PMID 16014059, PMID 18436082, PMID 21680850, PMID 22995802, PMID 24191893, PMID 24641955, PMID 27821627, PMID 28395659, PMID 29988921